For this open-label , randomised , phase 3 , hybrid-designed trial undertaken at 12 institutions or hospitals in China , we included Chinese patients aged 18-70 years with previously untreated , histologically confirmed metastatic triple-negative breast cancer , and an ECOG performance status of 0-1 .